Rafael Madero Marroquín, Hematology Oncology Fellow at The University of Chicago Medical Center, shared on X:
“CD58 loss has been described as a mechanism of resistance to blina and CAR-T therapy.
Our work suggests CD58 expression, using mean fluorescence intensity, does NOT impact the rate of flow MRD negativity after inotuzumab in B-ALL.
Thank you Anand Patel for your mentorship!”